BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

NCT06761911 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma (Category)

Interventions

DRUG: Brentuximab Vedotin (Bv)
DRUG: Sintilimab
DRUG: Tislelizumab
DRUG: Bendamustine

Sponsor

Xiuhua Sun